CalciMedica CALC 深 沪
已收盘 10-02 16:00:00 美东时间
1.60
-0.050
-3.03%
华盛通- 最 高1.70
- 今 开1.64
- 成交量 2.18万股
- 最 低 1.58
- 昨 收 1.65
- 总市值 1092.53万
- 52周最高 36.00
- 市盈率 静 --
- 换手率 0.32%
- 52周最低 1.58
- 委 比 52.76%
- 总股本 682.83万
- 历史最高 42.95
- 量 比 0.62
- 振 幅 7.27%
- 历史最低 1.58
- 每 手 1
- 风险率 9.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
CalciMedica, Inc. (Nasdaq: CALC), a clinical-stage biopharmaceutical company, announced that its Management will present and participate in 1x1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The Company is developing CRAC channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases. Its pipeline includes Auxora™ (zegocractin) for pulmonary arterial hyper...
09-08 11:00
CalciMedica Addresses Nasdaq Equity Compliance Amid Bid-Price Risk
An update from CalciMedica ( ($CALC) ) is now available. On August 31, 2026, Ca...
09-02 20:47
CalciMedica shares are trading lower after the company announced a 1-for-5 reverse stock split.
CalciMedica shares are trading lower after the company announced a 1-for-5 reverse stock split.
08-27 22:20
CalciMedica Announces 1-For-5 Reverse Stock Split, Effective August 28
CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that it will effect ...
08-27 21:01
CalciMedica Announces One-for-Five Reverse Stock Split
CalciMedica Inc. announced a 1-for-5 reverse stock split of its common stock, effective August 28, 2026. Trading on a split-adjusted basis will begin on August 31, 2026, under the symbol "CALC" with a new CUSIP number, 38942Q301. The reverse stock split aims to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. Shareholders will receive one share for every five shares held, reducing the total outstanding sh...
08-27 13:00
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
Guggenheim Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $9
Guggenheim analyst Vamil Divan initiates coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and announces Price Target of $9.
08-20 21:12
CalciMedica Q2 EPS $(0.45) Misses $(0.28) Estimate
CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.28) by 60.71 percent. This is a 12.5 percent decrease over losses of $(0.40) per share from the same period last year.
08-11 19:28
CalciMedica Receives No FDA Comments On The Submission Packet For Its Phase 2 KOURAGE Trial, Meaning The Company May Continue To Dose Patients With Auxora
CalciMedica, Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that the U.S. Food ...
06-24 19:05
